Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease
Growing evidence demonstrates that circulating tumor DNA (ctDNA) minimal residual
disease (MRD) following treatment for solid tumors predicts relapse. These results suggest …
disease (MRD) following treatment for solid tumors predicts relapse. These results suggest …
Life and death of circulating cell-free DNA
A Kustanovich, R Schwartz, T Peretz… - Cancer biology & …, 2019 - Taylor & Francis
Tumor-specific, circulating cell-free DNA in liquid biopsies is a promising source of
biomarkers for minimally invasive serial monitoring of treatment responses in cancer …
biomarkers for minimally invasive serial monitoring of treatment responses in cancer …
Bridging biological cfDNA features and machine learning approaches
T Moser, S Kühberger, I Lazzeri, G Vlachos, E Heitzer - Trends in Genetics, 2023 - cell.com
Liquid biopsies (LBs), particularly using circulating tumor DNA (ctDNA), are expected to
revolutionize precision oncology and blood-based cancer screening. Recent technological …
revolutionize precision oncology and blood-based cancer screening. Recent technological …
[HTML][HTML] The translational challenges of precision oncology
The translational challenges in the field of precision oncology are in part related to the
biological complexity and diversity of this disease. Technological advances in genomics …
biological complexity and diversity of this disease. Technological advances in genomics …
Current and future clinical applications of ctDNA in immuno-oncology
JC Stadler, Y Belloum, B Deitert, M Sementsov… - Cancer Research, 2022 - AACR
Testing peripheral blood for circulating tumor DNA (ctDNA) offers a minimally invasive
opportunity to diagnose, characterize, and monitor the disease in individual cancer patients …
opportunity to diagnose, characterize, and monitor the disease in individual cancer patients …
Predictive biomarkers for response to immune checkpoint inhibition
Immune checkpoint inhibitors have transformed the prognosis and treatment paradigm of
many cancer types, through the potential for durable responses. However, the majority of …
many cancer types, through the potential for durable responses. However, the majority of …
Future perspectives of uveal melanoma blood based biomarkers
Uveal melanoma (UM) is the most common primary intraocular malignancy affecting adults.
Despite successful local treatment of the primary tumour, metastatic disease develops in up …
Despite successful local treatment of the primary tumour, metastatic disease develops in up …
Circulating tumor DNA predicts outcome from first-, but not second-line treatment and identifies melanoma patients who may benefit from combination immunotherapy
Purpose: We evaluated the predictive value of pretreatment ctDNA to inform therapeutic
outcomes in patients with metastatic melanoma relative to type and line of treatment …
outcomes in patients with metastatic melanoma relative to type and line of treatment …
Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients
Abstract BRAF, NRAS and TERT mutations occur in more than 2/3 of melanomas. Its
detection in patient's blood, as circulating tumor DNA (ctDNA), represents a possibility for …
detection in patient's blood, as circulating tumor DNA (ctDNA), represents a possibility for …
Longitudinal monitoring of ctDNA in patients with melanoma and brain metastases treated with immune checkpoint inhibitors
Purpose: Brain involvement occurs in the majority of patients with metastatic melanoma. The
potential of circulating tumor DNA (ctDNA) for surveillance and monitoring systemic therapy …
potential of circulating tumor DNA (ctDNA) for surveillance and monitoring systemic therapy …